Pre-made Sevirumab benchmark antibody (Whole mAb, anti-HCMV (human cytomegalovirus) envelope glycoprotein H (gH) [Human betaherpesvirus 5] therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-HCMV (human cytomegalovirus) envelope glycoprotein H (gH) [Human betaherpesvirus 5] therapeutic antibody (Pre-made Sevirumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sevirumab (MSL-19) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.[1][2]
| Products Name (INN Index) | Pre-Made Sevirumab Biosimilar, Whole Mab: Anti-Hcmv (Human Cytomegalovirus) Envelope Glycoprotein H (Gh) [Human Betaherpesvirus 5] therapeutic antibody |
|---|---|
| INN Name | sevirumab |
| Target | HCMV (human cytomegalovirus) envelope glycoprotein H (gH) [Human betaherpesvirus 5] |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL?(Protein Design?Labs) BioPharma (Fremont CA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | HCMV (human cytomegalovirus) envelope glycoprotein H (gH) [Human betaherpesvirus 5] |
| Package |
